Any Chance for “Cures” Legislation This Year?
18 May 2016
Is there any chance “Cures” legislation will pass in 2016? Probably not by summer, as election-year activities will prompt an early exit from Washington. Thus the only chance for action on legislation promoting biomedical innovation is in a “lame duck” session of Congress in November. Rep. Fred Upton (R-Mich), lead House sponsor of the 21st Century Cures legislation, will no longer head the Energy & Commerce Committee next year due to House rules, and he is pressing hard for a final “Cures” bill to cap his tenure as chairman.
PhRMA member companies invested $58.8 billion in R&D in 2015
18 May 2016
For more than 30 years, the U.S. biopharmaceutical industry has been the world leader in the development of new medicines, driving innovation for patients. And PhRMA member companies continue to be at the forefront. According to the 2016 Biopharmaceutical Research Industry Profile and corresponding industry chart pack,Biopharmaceuticals In Perspective, released today, PhRMA member companies invested an estimated $58.8 billion in research and development (R&D) in 2015, up 10.3 percent from 2014.
Cross-country deals, new drug trials gain momentum in Asia
17 May 2016
George Yeh, president of Taiwan Liposome Co. Inc. (TLC), told BioWorld Asia that in the coming years more trials for new drugs would take place in Asia, and that cross-country collaborations will help train a new generation of doctors in how to detect the potency and effectivity of treatments yet to reach the market.
U.K.'s early access scheme working but challenges remain
17 May 2016
Two years after it was instituted, the U.K.'s Early Access to Medicines Scheme (EAMS) has succeeded in getting drugs to patients in advance of a formal marketing approval, but the aim that therapies arrive a year beforehand has not been met, and the fact the scheme is not funded makes it hard for small biotechs to participate.
16 May 2016
Syndax Pharmaceuticals (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today reported its financial results for the first quarter ended March 31, 2016, and provided a pipeline update and review of upcoming milestones. As of March 31, 2016, Syndax had $133.7 million in cash, cash equivalents and short-term investments.
Russian scientists work to ban “ride on virus”
16 May 2016
Biochemists in Novosibirsk, in Siberia, are looking for agents that are capable of suppressing the development and propagation of orthopoxviruses, a family of pathogenic viruses potentially dangerous to human beings, portal Science in Siberia reported.
Russian vaccine to prevent B-type hepatitis to hit global market
16 May 2016
A new Russian vaccine to prevent B-type hepatitis is entering the global market. According to experts, taking an injection with the new vaccine will give a person long-term confidence as it is said to stay active for many years.
Global regenerative medicine sector on a roll, report finds
16 May 2016
The Alliance for Regenerative Medicine (ARM) has released its first quarter industry report that describes a regenerative medicine sector, which includes gene and cellular therapies, in healthy shape. Growth is evident on a number of fronts, even in the wake of the uncertain financial environment that has prevailed and depressed the capital market since the beginning of the year.
13 May 2016
Tobira Therapeutics, Inc. ( NASDAQ : TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today announced that data from a study of cenicriviroc (CVC) in participants with liver cirrhosis and mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment, has been accepted as a manuscript for publication in the journal Clinical Translational Science.
U.S. probes contracts between drugmakers, pharmacy benefit managers
13 May 2016
The U.S. Attorney's Office for the Southern District of New York is investigating contracts between drugmakers and companies that manage prescription benefits, according to regulatory filings.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Four cancer centers opened in Russia in 2023
26 April 2024
Russia and the UAE can simplify the drug registration process
26 April 2024
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024